Albright Charles 4
4 · Editas Medicine, Inc. · Filed Dec 17, 2020
Insider Transaction Report
Form 4
Albright Charles
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-15$16.51/sh+10,000$165,100→ 34,907 total - Sale
Common Stock
2020-12-15$62.74/sh−5,776$362,386→ 29,131 total - Sale
Common Stock
2020-12-15$64.39/sh−200$12,878→ 24,907 total - Sale
Common Stock
2020-12-15$63.84/sh−4,024$256,892→ 25,107 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-15−10,000→ 145,000 totalExercise: $16.51Exp: 2026-09-08→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]The exercise and sale reported in this Form 4 was effected pursuant to a 10b5-1 plan adopted by the Reporting Person on May 15, 2020.
- [F2]This transaction was executed in multiple trades at prices ranging from $62.18 to $63.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $63.24 to $64.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This option was granted on September 9, 2016 and vested over four years with 25% of the shares having vested on August 22, 2017, and the remaining 75% of the shares having vested in equal monthly installments thereafter through August 22, 2020.